The development of improved and novel therapies is a main goal in oncology. Successful therapies should selectively target cancer cells. The analysis of the molecular and cellular differences between normal and malignant cells aims to identify specific therapeutic targets in tumor cells. Cancer is characterized by deregulated proliferation, and aberrant cell cycle control is an important difference between normal and malignant cells Pines, 1991, 1994; Hartwell and Kastan, 1994; Sherr, 1996; Malumbres and Barbacid, 2001) . Therefore, the identification of new prognostic parameters and therapeutic targets should be possible by analysing cell cycle regulation in cancer cells.
The cell cycle regulates cell growth and division to ensure that every cell receives a complete set of chromosomes. Missegregation of chromosomes results in aneuploidy. This may lead to overexpression of oncogenes or loss of tumor suppressor genes Loeb, 2001) . Moreover, mistakes during DNA replication can cause mutations, resulting in loss of function of tumor suppressor genes Loeb, 2001; Rouse and Jackson, 2002) . Such events are summarized under the term 'genomic instability' and are an important feature of cancer cells Loeb, 2001) . Genomic instability can be found in a wide variety of tumors, such as colon, breast, prostate, oropharynx or lung cancer, and leukemia and lymphoma (Lengauer et al., 1997; Cahill et al., 1998; Takahashi et al., 1999; Miyoshi et al., 2000; Saunders et al., 2000; Beheshti et al., 2001; Gu et al., 2002; Ru et al., 2002) . Different specific mutations of cell cycle regulators can thereby cause genomic instability resulting in a high number of random genetic mutations. This may explain the great diversity of mutations during tumorigenesis Loeb, 2001 ).
Proteolysis and cell cycle control
Cells have to grow to a certain size during the G1 phase of the cell cycle in order to avoid a decrease in cell size with each division. After reaching a certain size, cells pass a point of no return (restriction point in mammalian cells, start point in yeast) from which they have to complete an entire cell cycle. They also prepare for DNA replication during G1, which takes place in the subsequent S phase. After the G2 phase, where cells can repair potential DNA damage, cells enter mitosis or M phase. In mitosis, cells separate their chromosomes followed by exit from mitosis into the next G1 phase, from where cells can undergo differentiation or the cell division cycle can start again (Figure 1 ).
While the morphology of these events is known for over a century, most of the basic molecular mechanisms were discovered in recent years since the discovery of the cyclins two decades ago (Evans et al., 1983) . The cell cycle transitions are triggered by cyclin-dependent kinases (Cdks) activated by their regulating subunits, the cyclins, in all eucaryotes (Table 1) (Morgan, 1997; Miller and Cross, 2001) . Periodical oscillation of cyclins is central to cell cycle regulation. Cyclin activity has to be low during G1 to allow loading of pre-replication complexes (pre-RCs) onto replication origins in order to prepare for DNA replication. Firing of replication origins starts at the G1-S transition when cyclin activity increases. At the same time, the higher cyclin activity prevents reloading of pre-RCs and thereby limits DNA replication to once per cell cycle ensuring genomic integrity. In order to exit mitosis at the end of the cell cycle, cyclin activity has to drop again (King et al., 1996; Stillman, 1996) .
Proteolysis of cyclins and other cell cycle proteins is, besides transcriptional regulation of gene expression and inhibition by Cdk inhibitors (CKIs), pivotal to this oscillation pattern of cyclins and regulation of the cell cycle (King et al., 1996; Koepp et al., 1999) . Cyclins are degraded by the 26S proteasome after ubiquitination (Hershko and Ciechanover, 1998) . Rapid proteolysis of cell cycle regulators by the 26S proteasome depends on polyubiquitination by ubiquitin-protein ligases (E3). In order to transfer ubiquitin to a substrate, it has to be activated first through the formation of an ATPdependent thioester bond with the E1 ubiquitin-activating enzyme. Subsequently, ubiquitin is transferred to a cysteine residue of a ubiquitin conjugating enzyme (E2). Finally, ubiquitin is conjugated to a lysine residue of the target protein either directly or with assistance of a ubiquitin-protein ligase (E3), which functions in substrate recognition (Figure 2 ) (Hershko and Ciechanover, 1998) .
Two ubiquitin ligases are important during the cell cycle: the SCF complex (named after its three core components Skp1, Cdc53/Cullin and F-box protein) (Deshaies, 1999) and the large multisubunit complex APC (anaphase-promoting complex) (Table 2) (Morgan, 1999; Zachariae and Nasmyth, 1999; Harper et al., 2002; Peters, 2002) . The SCF complex regulates entry into S phase (Deshaies, 1999) by degradation of G1 CKIs, such as p27 and p21, and G1 cyclins (Deshaies, 1999; Spruck and Strohmaier, 2002a) . The APC is important for sister chromatid separation and exit from Figure 1 The cell cycle phases. In G1 cells grow and prepare for DNA replication in S phase. In the G2 phase, cells can repair potential DNA damage. In mitosis (M phase), cells separate their chromosomes followed by exit from mitosis into the next G1 phase, from where cells can arrest (G 0 ) and undergo differentiation (G T ) or the cell division cycle can start again. The SCF controls the G1-S transition and the APC mitosis and G1 Figure 2 Ubiquitin-dependent proteolysis. Proteasomal degradation of cell cycle regulators depends on polyubiquitination by ubiquitin-protein ligases or E3 (SCF, APC). (1) Ubiquitin is activated by the formation of an ATP-dependent thioester bond with the ubiquitin-activating enzyme (E1). (2) Ubiquitin is transferred to a cysteine residue of a ubiquitin conjugating enzyme (E2). (3) Ubiquitin is conjugated to a lysine residue of the target protein either directly or with assistance of a ubiquitin-protein ligase (E3), which functions in substrate recognition. The ubiquitinated protein is recognized and degraded by the 26S proteasome 
S.c., Saccharomyces cerevisiae APC-dependent proteolysis and genomic instability R Wäsch and D Engelbert mitosis by degrading substrates, such as securin and mitotic cyclins (Morgan, 1999; Zachariae and Nasmyth, 1999; Harper et al., 2002; Peters, 2002 ) (Bai et al., 1996; Kipreos and Pagano, 2000) , whereas the APC is activated by the regulatory subunits Cdc20 (APC Cdc20 ) and Cdh1 (APC Cdh1 ), which also confer some substrate specificity (Schwab et al., 1997; Visintin et al., 1997) . The APC recognizes two different amino-acid sequences. The destruction box (D box) with the consensus sequence RxxLxxxxN (Glotzer et al., 1991) is recognized by APC Cdc20 and APC
Cdh1
, and APC Cdh1 also recognizes the KEN box (Pfleger and Kirschner, 2000; Burton and Solomon, 2001 ).
Role of APC-dependent cyclin proteolysis in the regulation of mitosis and genomic stability Human cells share many cell cycle mechanisms with simpler organisms, such as yeast. It is also much easier to work with yeast organisms since they are readily genetically tractable and divide much faster. Therefore, they are ideal models for studying how cell cycle control may work in humans as well as how it can malfunction in cancer. Most of our knowledge regarding the regulation of the cell cycle comes from yeast. Thus, it is important to understand central results from this model in order to apply it to the human cell cycle and cancer research.
To exit mitosis into a next G1 phase of the cell cycle, mitotic kinase inactivation is required (Morgan, 1999; Zachariae and Nasmyth, 1999; Harper et al., 2002; Peters, 2002) . Several laboratories have first proposed that proteolysis of the main mitotic cyclin Clb2 of Saccharomyces cerevisiae (which is comparable to human cyclin B1) (Table 1) seems to be important, but not essential for mitotic exit (Amon et al., 1994; Schwab et al., 1997; Cross et al., 1999) . It has also been shown that Clb2 proteolysis is regulated by the APC activated by Cdh1 (APC Cdh1 ) (Schwab et al., 1997; Visintin et al., 1997) . Cdh1 deletion mutants are viable, but inactivation of Cdh1 and the CKI Sic1 is lethal (Schwab et al., 1997; Visintin et al., 1997) . Therefore, it was proposed that APC Cdh1 -dependent Clb2 proteolysis combined with inactivation of Clb2-Cdk1 kinase activity by the CKI Sic1 (functionally comparable with human p21 and p27) is essential for mitotic exit (Schwab et al., 1997; Visintin et al., 1997) . Proteolysis of securin, an important protein for sister chromatid separation, and the S phase cyclin Clb5 (structurally a B-type cyclin, functionally comparable to cyclin A2) (Table 1) by APC Cdc20 appeared in complex knockout studies to be critical for mitotic exit (Shirayama et al., 1999) . It was concluded that degradation of securin and Clb5 by APC Cdc20 results in activation of APC Cdh1 and the CKI Sic1, both inactivating Clb2 and allowing mitotic exit. Next, it was demonstrated that there are two phases of Clb2 degradation, a first phase in meta-and anaphase depending on APC Cdc20 and a second phase in late mitosis and G1 on APC Cdh1 (Ba¨umer et al., 2000; Yeong et al., 2000; Wa¨sch and Cross, 2002) . By blocking degradation of the S phase cyclin Clb5 and the mitotic cyclin Clb2, the proteolysis of these major B cyclins in S. cerevisiae was analysed directly at endogenous expression levels (Wa¨sch and Cross, 2002) . These experiments demonstrated that proteolysis of the mitotic cyclin Clb2, and not the S phase cyclin Clb5, is essential for mitotic exit, and that combined deletion of Cdh1 and Sic1 does not block mitotic exit (spindle disassembly and cytokinesis) (Wa¨sch and Cross, 2002) . Taken all these data together, it was proposed that the first phase of Clb2 proteolysis by APC Cdc20 (Ba¨umer et al., 2000; Yeong et al., 2000; Wa¨sch and Cross, 2002 ) is sufficient for spindle disassembly and cytokinesis (Wa¨sch and Cross, 2002) . APC Cdh1 was found to be important for inactivating Clb2 during mitotic exit and the G1 phase of the cell cycle mainly to regulate cell growth and the length of G1, which might be necessary for cell differentiation and for correct assembly of pre-RCs at origins of replication and subsequent complete and accurate DNA replication , even in yeast, is not easy to dissect due to some overlap in function (Wa¨sch and Cross, 2002; Cross, 2003) . But the embryonic cell cycle already indicated that APC Cdc20 function is sufficient to allow oscillation of Figure 3 Model of the regulation of mitosis and G1 by APCdependent cyclin proteolysis. The first phase of cyclin B1/Clb2 proteolysis by APC Cdc20 mediates spindle disassembly and cytokinesis. APC Cdc20 -dependent degradation of cyclin A2/Clb5 leads to activation of Cdh1 and in yeast of the CKI Sic1 downregulating mitotic kinase activity in G1. Whether there is any role of human CKIs such as p21 or p27 in this context has to be defined. APC Cdh1 inactivates cyclin B1/Clb2 further during mitotic exit and the G1 phase of the cell cycle to regulate cell growth and the length of G1 allowing cell differentiation and correct assembly of pre-RCs at origins of replication and subsequent complete and accurate DNA replication APC-dependent proteolysis and genomic instability R Wäsch and D Engelbert mitotic cyclins and alternation of S and M phase, whereas APC Cdh1 occurs only in the somatic cell cycle to establish an intermittent G1 phase (King et al., 1996; Sigrist and Lehner, 1997; Lorca et al., 1998) .
Cyclin A2 proteolysis in human cells begins in early prometaphase and is completed at metaphase (den Elzen and Pines, 2001; Geley et al., 2001) . Degradation of cyclin A2 is inhibited by injection of antibodies against Cdc27 and Cdc20, suggesting that APC Cdc20 degrades cyclin A2 in early prometaphase (Geley et al., 2001 ). Cyclin A2 is also a substrate of APC Cdh1 , keeping cyclin A2 activity low during G1 (Sorensen et al., 2000 (Sorensen et al., , 2001 Geley et al., 2001) . Mutation of the destruction box alone does not stabilize cyclin A and the degradation signal is more complex (den Elzen and Pines, 2001; Geley et al., 2001; Jacobs et al., 2001) . Overexpression of stable cyclin A2 in human cells can delay chromosome alignment and sister chromatid segregation (den Elzen and Pines, 2001) or arrest cells in anaphase (Geley et al., 2001) . Expression of stable cyclin A at endogenous expression levels had little effect on mitosis at least in flies, but is required for G1 arrest (Jacobs et al., 2001) . The role of cyclin A2 degradation in human cells at endogenous expression is not clear to date and remains to be defined. Cyclin A2 disappears before cyclin B1 in the cell cycle. Activation of the spindle checkpoint, which delays the metaphase to anaphase transition until all chromosomes are attached to the mitotic spindles, inhibits cyclin B1, but not cyclin A2 degradation, implying that different forms of APC Cdc20 are involved (den Elzen and Pines, 2001; Geley et al., 2001) . Thus, a form of APC Cdc20 that is not inhibited by the spindle checkpoint may promote cyclin A2 degradation, whereas a form that can be inhibited by the spindle checkpoint may be responsible for cyclin B1 destruction (den Elzen and Pines, 2001; Geley et al., 2001) .
Cyclin B1 in mammalian cells is degraded mainly before the onset of anaphase (Clute and Pines, 1999) . Expression of a nondegradable form of cyclin B1 can lead to an anaphase-like arrest in mammalian cells unable to undergo cytokinesis (Wheatley et al., 1997) . However, recent results indicate that a nondegradable form of cyclin B1 may block already the metaphase to anaphase transition in human cells (Chang et al., 2003) and frog eggs (Stemmann et al., 2001) . The exact phenotype depends on the amount of nondegradable cyclin B1 expressed in the cell (Stemmann et al., 2001; Hagting et al., 2002; Chang et al., 2003) . Similarly, as in yeast (Wa¨sch and Cross, 2002) , more experiments with expression of the nondestructible cyclin B1 (as well as cyclin A2) from the endogenous promoter, mimicking more closely endogenous expression levels and promoter regulation, might clarify the role of cyclin B1 (cyclin A2) destruction in human cells more definitely. Degradation of human cyclin B1 is completed when cells enter anaphase (Clute and Pines, 1999) implying that APC Cdc20 is required for cyclin B1 degradation. The exact role of Cdh1 and whether proteolysis of some cyclin B1 by APC Cdh1 in late mitosis is required for exit from mitosis or regulation of G1 in higher eucaryotes and humans is not known to date. As in the budding yeast model, where the first phase of Clb2 degradation by APC Cdc20 (Ba¨umer et al., 2000; Yeong et al., 2000; Wa¨sch and Cross, 2002 ) is already sufficient for most aspects of mitotic exit (Wa¨sch and Cross, 2002) , the main role of Cdh1 perhaps in concert with CKIs like p21 and p27 in mammalian cells is also very likely the regulation of a stable G1 and accurate DNA replication by keeping mitotic cyclins low during G1 (Figure 3) . APC Cdh1 may also play an important role in differentiation, since it controls axonal growth and morphogenesis in postmitotic neurons in mammalian cells (Konishi et al., 2004) . APC Cdh1 has also been linked to TGF-mediated control of cell growth and differentiation (Stroschein et al., 2001; Wan et al., 2001 ).
Regulation of APC activity
Several mechanisms are involved in the regulation of APC activity. The APC is active from mitosis until the end of G1 (Amon et al., 1994; Brandeis and Hunt, 1996) . The affinity of activators of the APC is regulated by phosphorylation of APC subunits (Kotani et al., 1999; Kramer et al., 2000; Kraft et al., 2003) . Cdc20 activity is regulated by transcription and APC Cdh1 -dependent degradation leading to APC Cdc20 activity from early mitosis until the M to G1 transition (Fang et al., 1998b; Prinz et al., 1998; Shirayama et al., 1998; Pfleger and Kirschner, 2000; Huang et al., 2001 ). Cdk1 and MAPK can phosphorylate Cdc20; although it is controversial whether phosphorylation of Cdc20 is necessary for APC activation in human cells (Kotani et al., 1999; Kramer et al., 2000; Yudkovsky et al., 2000) , it is required for its inhibition by the spindle checkpoint (Chung and Chen, 2003) .
Initially it has been reported that the protein level of Cdh1 remains relatively constant throughout the cell cycle (Fang et al., 1998b; Prinz et al., 1998) and Cdh1 is activated by dephosphorylation from the M to G1 transition until the end of the G1 phase Jaspersen et al., 1999; Lukas et al., 1999; Kramer et al., 2000) . However, there are also reports that Cdh1 levels oscillate during the cell cycle at least in human cells Hsu et al., 2002) . The subcellular localization of Cdh1 is cell cycle regulated (Jaquenoud et al., 2002; Zhou et al., 2003) and Cdh1 is nuclear during G1 and in the cytoplasm between S phase and the end of mitosis (Jaquenoud et al., 2002) . Cdkdependent phosphorylation leads to efficient inactivation of Cdh1 by nuclear export (Jaquenoud et al., 2002) and prevention of APC binding Jaspersen et al., 1999; Lukas et al., 1999; Kramer et al., 2000) , thus restricting APC Cdh1 activity to the points in the cell cycle when Cdk activity is low.
Phosphorylation of core APC subunits upon entry into mitosis by Cdk1/cyclin B and polo protein kinases Plk/Cdc5/Plo1 (Descombes and Nigg, 1998; Kotani et al., 1998 Kotani et al., , 1999 ) enhances Cdc20-APC interaction (Fang et al., 1998b; Kramer et al., 1998) . One or more subunits (Apc1, Cdc27, Cdc16 and Cdc23) are phosphorylated during mitosis (Kotani et al., 1998; and dephosphorylation can inactivate the mitotic APC (Lahav-Baratz et al., 1995) . Dephosphorylation of Cdk1-phosphorylation sites of the APC may inactivate the mitotic APC Cdc20 by dissociation of Cdc20, and Cdh1 then replaces Cdc20, leading to degradation of Cdc20 during mitotic exit and G1 Hagting et al., 2002; Kraft et al., 2003) . On the other hand, protein kinase A (PKA)-mediated phosphorylation of core APC subunits can also inhibit APC activity (Kotani et al., 1998 (Kotani et al., , 1999 and dephosphorylation of PKA phosphorylation sites, possibly by the phosphatases (PPs) PP1 (Ishii et al., 1996) or PP2A (Bastians et al., 1999) , increases APC activity and Cdc20 binding. Therefore, the phosphorylation of some subunits may have activating effects, whereas the phosphorylation of other subunits may have inhibitory effects. However, the precise nature of these phosphorylation/dephosphorylation events and how they affect APC regulation still remains to be elucidated in more detail.
Mitotic control by the APC

APC
Cdc20 degrades cyclin A (Geley et al., 2001) , which may lead to decreased phosphorylation and activation of Cdh1 (Figure 3) Shirayama et al., 1999) . APC (Stemmann et al., 2001 ). Securin degradation not only promotes sister chromatid separation but also releases the phosphatase Cdc14 from the nucleolus. The Cdc14 protein is part of a complex mitotic exit network (Bardin and Amon, 2001 ). Release of Cdc14 leads to dephosphorylation and activation of Cdh1 Shirayama et al., 1999; Bembenek and Yu, 2001; Stegmeier et al., 2002) . Activated APC Cdh1 finally degrades mitotic cyclins further at the M to G1 transition and maintains their low state of activity during G1 (Figure 3) (King et al., 1996; Sigrist and Lehner, 1997; Lorca et al., 1998; Wa¨sch and Cross, 2002; Cross, 2003) .
Deregulated proteolysis in cancer
Deregulation of cyclins and other cell cycle regulators can cause aberrant proliferation and genomic instability (Spruck et al., 1999; Lengronne and Schwob, 2002; Sarafan-Vasseur et al., 2002; Wa¨sch and Cross, 2002) . Aberrant expression of different cyclins can be detected in various malignant tumors Chetty, 1998, 1999; Yam et al., 2002) , with important implications for clinical oncology. One recent example is the prognostic relevance of the elevated cyclin E expression in breast cancer (Keyomarsi et al., 2002; Sutherland and Musgrove, 2002) . In a multivariate analysis, a high cyclin E level was significantly correlated with poor outcome in breast cancer patients and demonstrates the importance of cell cycle proteins to improve riskadapted therapy.
Various mechanisms, such as gene amplification or overexpression, missing inactivation by CKI and unregulated proteolysis, can result in deregulation of cyclins. Thus, deregulated proteolysis of cyclin E may play a role in tumorigenesis. Cyclin E degradation is SCF dependent (Koepp et al., 2001; Moberg et al., 2001; Strohmaier et al., 2001 ) and elevated cyclin E levels result in genomic instability (Spruck et al., 1999) . The Fbox protein, which is mediating the SCF-dependent proteolysis of cyclin E, could be identified as a homolog of the S. cerevisiae protein Cdc4 (Koepp et al., 2001; Strohmaier et al., 2001) . Indeed, Cdc4 can be mutated in breast, endometrial and ovarian cancer cells, with high levels of cyclin E as a result of reduced cyclin E proteolysis (Moberg et al., 2001; Strohmaier et al., 2001; Spruck et al., 2002b) . Cdc4 is also mutated in genetically instable colon cancers and their precursor lesions, indicating that early specific mutations might result in aneuploidy being responsible for malignant progression (Rajagopalani et al., 2004) . In colon cancer, a decreased or absent activity of the CKI p27 could be found due to increased degradation (Loda et al., 1997) . Decreased levels of p27 have also been found in breast cancer (Catzavelos et al., 1997; Porter et al., 1997) . Absent inhibition by p27 also results in high cyclin E activity that may lead to genomic instability.
The APC substrate securin is important for sister chromatid separation and is involved in tumorigenesis (Zou et al., 1999a) . Securin is frequently overexpressed in hematopoietic neoplasms (Dominguez et al., 1998; Saez et al., 2002) . Deletion of securin as well as blocked APC-dependent proteolysis and genomic instability R Wäsch and D Engelbert proteolysis of securin by APC Cdc20 both lead to genomic instability Hagting et al., 2002) . This paradox may be explained by the fact that securin is required to fully activate separase and, therefore, loss of securin as well as undegradable securin leads to inactive separase with problems in sister chromatid separation and loss of chromosomes. Also, high B cyclin levels result in genomic instability (Sarafan-Vasseur et al., 2002; Wa¨sch and Cross, 2002) and can be found in colon (SarafanVasseur et al., 2002; Wang et al., 2003) or lung cancer (Soria et al., 2000) . Deregulation of APC-dependent proteolysis of these substrates is thereby important and very likely to be involved in tumorigenesis. Since most knowledge about APC regulation was published in recent years, little is known about the relevance of these mechanisms in the development of cancer. Reduced expression of the APC regulatory subunit Cdh1 has been described during the malignant progression of a Blymphoma cell line (Wang et al., 2000) , and recently it has been demonstrated that several heterozygote mutations of APC subunit genes can be found in colon cancer cells . Moreover, overexpression of a mutated APC8/CDC23 gene in a colon cancer cell line leads to deregulation of cyclin B protein levels and cell cycle progression . Cyclin A is overexpressed in a variety of cancers (Yam et al., 2002) and can stimulate genomic instability (Vaziri et al., 2003) . It will be of interest to see whether deregulated APC-dependent proteolysis is also involved.
Uncontrolled APC activity may lead to genetic instability in various ways and multiple steps. A decrease or loss of APC Cdh1 activity may cause higher cyclin A2 activity during G1, which may shorten the length of G1 by driving cells into precocious S phase. A shortened G1 may result in decreased loading of preRCs onto replication origins leading to a prolonged DNA replication. Residual cyclin B1 activity after mitotic exit in cells without APC Cdh1 may over-ride an S/M checkpoint and lead to premature entry into mitosis and chromosome segregation of incompletely replicated DNA causing double-strand breaks and genetic instability. In addition, a lower number of fired replication origins with ongoing replication forks might not efficiently activate an S/M checkpoint.
A further substrate of APC Cdh1 is the Aurora A kinase (Castro et al., 2002; Littlepage and Ruderman, 2002; Taguchi et al., 2002) . Aurora A accumulates in G2/M phase and is involved in centrosome duplication and separation and in spindle assembly (Carmena and Earnshaw, 2003) . Aurora A regulates centrosome maturation and is essential for the recruitment of cyclin B1-Cdk1 complexes to centrosomes (Hirota et al., 2003) . Cyclin B1-Cdk1 then becomes activated at centrosomes, which is required for entry into mitosis (Hirota et al., 2003) . Centrosomes in Aurora A-depleted HeLa cells remained immature (Hirota et al., 2003) . Elevated levels of Aurora A have been described in human cancers (Zhou et al., 1998; Sen et al., 2002; Ewart-Toland et al., 2003; Gritsko et al., 2003; Hamada et al., 2003; Li et al., 2003) . Aurora A overexpression induces resistance to the chemotherapeutic agent paclitaxel by overriding the spindle checkpoint (Anand et al., 2003) . Aberrant high levels of Aurora A do not affect centrosome duplication directly, but lead to cells passing through mitosis without cytokinesis, producing tetraploid progeny, which gives rise to aneuploid cells in the subsequent cell division cycle particularly in the absence of the tumor suppressor p53 (Meraldi et al., 2002; Katayama et al., 2003) .
A critical role for the regulation of DNA replication, by licensing origin firing, has been ascribed to Cdc6 to ensure that initiation of replication occurs only once per cell cycle. Thereby, Cdc6 promotes the assembly of preRCs at origins of DNA replication. Regulation of human Cdc6 involves periodical transcription, inactivation by Cdk-dependent phosphorylation, leading to nuclear export in S, G2 and mitosis and ubiquitindependent degradation mediated by APC Cdh1 in early G1 (Saha et al., 1998; Jiang et al., 1999; Petersen et al., 1999; Petersen et al., 2000) . These mechanisms limit Cdc6 activity to a part of G1 and are required for inhibition of reassembly of pre-RCs. Overexpression of Cdc6, as well as Cdt1, another protein involved in the formation of pre-RCs, alone or in combination results in re-replication and genetic instability in cells with inactive p53 (Vaziri et al., 2003) , which is a common feature of cancer cells. Re-replication is stimulated by cyclin ACdk2 activity (Vaziri et al., 2003) . Overexpression of Cdc6 in cervical dysplasia and carcinoma (Williams et al., 1998) and brain tumors (Ohta et al., 2001) , as well as downregulation of Cdc6 in prostate cancer, suggests a possible role for Cdc6 in carcinogenesis and cancer progression (Robles et al., 2002) . Stabilized Cdc6 can be found in endoreplicating cells (Bermejo et al., 2003) , implying a possible role of deregulated proteolysis of Cdc6 in the development of genetically instable cancer cells.
A newly identified APC Cdh1 target is the F-box protein Skp2, which mediates the degradation of p27 and p21 at the G1-S transition. Silencing of Cdh1 stabilizes Skp2, which in turn reduces the activity of p27 and p21 in G1 contributing to premature S phase entry (Bashir et al., 2004; Wei et al., 2004) . This is another example demonstrating the importance of APC Cdh1 in maintaining a stable G1 phase.
Mitotic checkpoints involving APC regulation and tumorigenesis
A late prophase checkpoint ensuring the delay for the precise timing mechanism of APC activation and cyclin B destruction is mediated by the APC inhibitor Emi1, a conserved F-box protein (Figure 4) (Reimann et al., 2001a) . By inhibiting Cdc20 and Cdh1, Emi1 defines an interval of cyclin stability and APC inactivity (Reimann et al., 2001a, b; Hsu et al., 2002) . Emi1 promotes accumulation of normal levels of cyclin A by inhibition of APC Cdh1 activity at G1/S and entry into S phase (Hsu et al., 2002) . Emi1 also regulates mitotic entry by inhibiting APC Cdc20 in order to allow accumulation of cyclin B (Reimann et al., 2001a) . Proteolytic Emi1 destruction is ubiquitin dependent and its corresponding ubiquitin ligase is SCF betaTrCP/Slimb . Failure of Emi1 destruction by inactivation of the F-box protein beta-TrCP1 causes stabilization of APC substrates in mouse embryonic fibroblasts, leading to mitotic catastrophe, including centrosome overduplication, multipolar metaphase spindles and misaligned chromosomes (Guardavaccaro et al., 2003; MargottinGoguet et al., 2003) . The important role of Emi1 in APC inhibition and control of S phase and mitotic entry makes it a good candidate for a potential involvement in tumorigenesis. Emi1 overexpression can be found in various cancers (Hsu et al., 2002) and therefore might lead to genetic instability by deregulating APC activity in these tumors.
A specific mechanism to guarantee genomic integrity is supplied by the spindle assembly checkpoint (Musacchio and Hardwick, 2002; Cleveland et al., 2003) . This cell cycle checkpoint is responsible for ensuring the bilateral attachments of all pairs of sister chromatids to the mitotic spindle. Thereby, the precise spatial orientation of chromosomes is detected and the onset of anaphase is delayed until all the mitotic spindle microtubules are attached to the kinetochores at the centromeres of the chromosomes. The spindle checkpoint is regulated by signaling mechanisms, involving the Bub1, BubR1 (Mad3 in mammals), Bub3, Mps1, Mad1 and Mad2 gene products. The Bub and Mad genes are well conserved from yeast to human and function as inhibitors of the APC, by preventing interaction with its activating phosphorylated subunit Cdc20 (Figure 4 ) (Fang et al., 1998a; Hwang et al., 1998; Kim et al., 1998; Wassmann and Benezra, 1998) . Recently, it has been shown that interaction between Mad2 and Cdc20 requires Cdk activity (Chung and Chen, 2003; D'Angiolella et al., 2003) . When the spindle checkpoint is activated, the proteolytic destruction of securin (Zur and Brandeis, 2001 ) and cyclin B (Raff et al., 2002) by APC Cdc20 is inhibited, which leads to cell cycle arrest with unseparated chromatids (Cohen-Fix et al., 1996; Zou et al., 1999b) , avoiding the risk of chromosome missegregation and mitotic catastrophe. Spindle checkpointdeficient cells develop numerical chromosome instabilities, as reported for a number of different cancers such as colon, lung, breast and bladder cancer, and leukemia and lymphoma cells, where mutations in the Mad and Bub genes are identified especially in the kinetochore localization domain (Cahill et al., 1998; Masuda and Takahashi, 2002; Ru et al., 2002) .
Targeted therapy
New detected differences in cell cycle regulation by proteolysis in tumor cells could have prognostic relevance. Moreover, such tumor-specific differences could be important new therapeutic targets. Like STI571, a specific inhibitor of the BCR-ABL tyrosine kinase, in the therapy of chronic myeloid leukemia (CML) (Druker et al., 2001a, b) , synthetic CKIs (Senderowicz, 2001; Carnero, 2002) or proteasome inhibitors (Adams, 2002; Almond and Cohen, 2002; Goldberg and Rock, 2002) and their targeted use could be efficient in various tumors. Clinical trials with these substances have already started, such as phase I-III studies with the proteasome inhibitor bortezomib (PS-341, Velcade s ) in refractory hematologic malignancies, especially multiple myeloma, or a phase I study with the CKI Flavopiridol in advanced solid tumors and lymphomas (Orlowski et al., 2002; Tan et al., 2002; Richardson et al., 2003) .
Nevertheless, to exploit the striking differences between normal and malignant cells and grant patients a well-tolerable treatment, more specific inhibitors of proteolysis, for example, blocking substrate recognition by E3 ubiquitin ligases, must be detected. One approach to achieve this could be inhibition of different F-box proteins that confer substrate specificity to the SCF. One of those F-box proteins, representing a new target for a therapeutic approach, is the S phase kinaseassociated protein 2 (Skp2). Downregulation of Skp2 by antisense RNA treatment induces apoptosis in lung cancer cells (Yokoi et al., 2003) . Recent work has identified 1,25-dihydroxyvitamin D3, or its analog EB1089, as an inhibitor of the F-box protein Skp2 that targets p27 for destruction, inducing growth arrest in cancer cells due to high levels of p27 (Lin et al., 2003) . Expression of Skp2 in EB1089-treated cells was reduced, whereas gene transcription of p27 was not affected (Lin et al., 2003) . The growth arrest was due to an increased stability of p27 protein levels (Lin et al., 2003) . Skp2 expression is also affected by treatment with retinoic acid, thus altering the ability of p27 to be ubiquitinated (Nakamura et al., 2003) . Troglitazone belongs to a group of ligands for peroxisome proliferator-activated receptor gamma (PPARgamma) (Koga et al., 2003) . Its antitumoral effects in human hepatoma cells are also due to a decreased gene expression of Skp2 at the mRNA level, leading to the accumulation of p27 (Koga et al., 2003) . Targeting the APC by specific inhibitors of the multiple subunits is another very promising approach for a more specific cancer therapy and subject of ongoing research. RNA interference (Elbashir et al., 2001 ) is thereby a powerful tool to validate APC subunits as potential targets.
Concluding remarks
Specific mutations of cell cycle regulators can likely be targeted early in tumor progression by small molecule drugs, but can also result in unspecific genomic instability during tumor progression with variable genetic mutations, impossible to be targeted therapeutically at these later stages. Taken the crucial role of proteolysis in cell cycle regulation and control of genomic integrity, it is of fundamental importance to develop highly specific inhibitors of the ubiquitin ligases SCF and APC in order to interfere with deregulated proteolysis in human cancer cells. Cancer cells with uncontrolled proteolysis of cell cycle regulators may be more sensitive to such drugs than normal cells, allowing the application of lower doses and therefore limiting the side effects of these more specific inhibitors. The ultimate goal will be to develop drugs, which interfere only with a mutated regulator of proteolysis and cell cycle control and thereby just affecting the cancer cell.
